ArticleJournal of pharmacy & bioallied sciences2025
Exploring GABA - A Receptor Subunit Mutations and Their Role in Epilepsy Pathophysiology.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epilepsy, marked by recurrent seizures, often arises from impaired inhibitory neurotransmission. Gamma-aminobutyric acid type A (GABA_A) receptors, particularly the α1 subunit encoded by GABRA1, are central to neuronal excitability. Although GABRA1 variants are linked to epilepsy, their molecular impact remains unclear. Objectives: To evaluate the structural and functional consequences of GABRA1 variants using computational approaches and clarify their role in epilepsy pathophysiology. Materials and Methods: A total of 137 GABRA1 missense variants were retrieved from ClinVar. Pathogenicity was assessed using ClinPred, REVEL, and FATHMM-XF. Conservation analysis was performed with ConSurf, and structural modeling with the HOPE server and UCSF Chimera. Functional domain mapping utilized UniProt and NCBI databases. Results: Eight variants (L49H, P59L, W97R, D99G, G152S, V270G, T294R, P305L) were consistently predicted to be deleterious. These mutations, mostly at conserved residues, localized to extracellular, ligand-binding, and transmembrane domains. Structural modeling revealed disruptions in receptor folding, ligand binding, and ion channel gating, indicating impaired GABAergic signaling and possible links to drug resistance. Conclusion: In silico analysis highlights critical GABRA1 variants that may drive epileptogenesis by altering receptor structure and function. These findings support integrating computational genomics into precision medicine strategies for epilepsy management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.